1. Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity.
- Author
-
Peng L, Zhou L, Li H, Zhang X, Li S, Wang K, Yang M, Ma X, Zhang D, Xiang S, Duan Y, Wang T, Sun C, Wang C, Lu D, Qian M, and Wang Z
- Subjects
- Animals, Humans, Mice, YAP-Signaling Proteins metabolism, Cell Line, Tumor, Adaptor Proteins, Signal Transducing metabolism, Adaptor Proteins, Signal Transducing genetics, Neoplasms immunology, Neoplasms pathology, Neoplasms metabolism, Mice, Inbred C57BL, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Intracellular Signaling Peptides and Proteins metabolism, Intracellular Signaling Peptides and Proteins genetics, T-Lymphocytes, Cytotoxic immunology, Transcription Factors metabolism, Antigen Presentation immunology, Histocompatibility Antigens Class I metabolism, Histocompatibility Antigens Class I immunology, Histocompatibility Antigens Class I genetics, Hippo Signaling Pathway, Signal Transduction, Protein Serine-Threonine Kinases metabolism
- Abstract
The major histocompatibility complex class I (MHC class I)-mediated tumor antigen processing and presentation (APP) pathway is essential for the recruitment and activation of cytotoxic CD8
+ T lymphocytes (CD8+ CTLs). However, this pathway is frequently dysregulated in many cancers, thus leading to a failure of immunotherapy. Here, we report that activation of the tumor-intrinsic Hippo pathway positively correlates with the expression of MHC class I APP genes and the abundance of CD8+ CTLs in mouse tumors and patients. Blocking the Hippo pathway effector Yes-associated protein/transcriptional enhanced associate domain (YAP/TEAD) potently improves antitumor immunity. Mechanistically, the YAP/TEAD complex cooperates with the nucleosome remodeling and deacetylase complex to repress NLRC5 transcription. The upregulation of NLRC5 by YAP/TEAD depletion or pharmacological inhibition increases the expression of MHC class I APP genes and enhances CD8+ CTL-mediated killing of cancer cells. Collectively, our results suggest a crucial tumor-promoting function of YAP depending on NLRC5 to impair the MHC class I APP pathway and provide a rationale for inhibiting YAP activity in immunotherapy for cancer., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF